SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001576885-23-000058
Filing Date
2023-11-13
Accepted
2023-11-13 07:20:00
Documents
17
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abos-20231113.htm   iXBRL 8-K 31774
2 EX-99.1 abos-20231113xexx991.htm EX-99.1 127819
3 EX-99.2 abos-20231113xexx992.htm EX-99.2 11778
7 g410427g05v05a.jpg GRAPHIC 13772
8 g410427g06v12a.jpg GRAPHIC 13113
9 image_0.jpg GRAPHIC 36458
  Complete submission text file 0001576885-23-000058.txt   406128

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abos-20231113.xsd EX-101.SCH 1901
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abos-20231113_lab.xml EX-101.LAB 24833
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abos-20231113_pre.xml EX-101.PRE 13043
11 EXTRACTED XBRL INSTANCE DOCUMENT abos-20231113_htm.xml XML 2809
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 231395079
SIC: 2836 Biological Products, (No Diagnostic Substances)